Domov › Nemalobunkový karcinóm pľúc › Ohio › Akron
Klinické štúdie Nemalobunkový karcinóm pľúc v meste Akron, OH
22 štúdií pre Nemalobunkový karcinóm pľúc hľadá účastníkov v zariadeniach v meste Akron a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Prebieha náborFáza 3
- Cleveland Clinic Akron General, Akron
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Prebieha náborFáza 3
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
Prebieha náborFáza 3
- Akron General Medical Center, Akron
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Research Site, Canton · 21 míľ odtiaľ
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Aultman North, North Canton · 15 míľ odtiaľ
- Aultman Massillon, Massillon · 20 míľ odtiaľ
- Aultman Orrville Hospital, Orrville · 21 míľ odtiaľ
- a 2 ďalších
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Prebieha náborFáza 3
- Aultman Hospital, Canton · 21 míľ odtiaľ
Pan-tumor MRD Study
Prebieha náborObservačná štúdia
- Gabrail Cancer Center, Canton · 21 míľ odtiaľ
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Prebieha náborFáza 2/3
- Gabrail Cancer Center Research, Canton · 21 míľ odtiaľ
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
Prebieha náborFáza 2
- Gabrail Cancer Center, Canton · 21 míľ odtiaľ
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Prebieha náborFáza 2/3
- Tricounty Hematology and Oncology - Massillon, Massillon · 20 míľ odtiaľ
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
Prebieha náborFáza 1/2
- Gabrail Cancer Center Research, Canton · 21 míľ odtiaľ
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Prebieha náborFáza 3
- Gabrail Cancer Center, Canton · 21 míľ odtiaľ
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Prebieha náborFáza 2
- Gabrail Cancer and Research Center, Canton · 21 míľ odtiaľ
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Cleveland Clinic Mercy Hospital, Canton · 21 míľ odtiaľ
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2/3
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Prebieha náborFáza 2
- Aultman Health Foundation, Canton · 21 míľ odtiaľ
GEMINI-NSCLC: NSCLC Biomarker Study
Prebieha náborObservačná štúdia
- Aultman Hospital, Canton · 21 míľ odtiaľ
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Prebieha náborFáza 1
- Gabrail Cancer & Research Center, Canton · 21 míľ odtiaľ
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Research Site 138, Canton · 21 míľ odtiaľ
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
Prebieha náborFáza 1/2
- Gabrail Cancer Center Research, Canton · 21 míľ odtiaľ
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Prebieha náborFáza 1/2
- Gabrail Cancer Research Center, Canton · 21 míľ odtiaľ
Štúdie Nemalobunkový karcinóm pľúc v iných mestách
- Houston, TX145 štúdií
- New York City, NY121 štúdií
- Arlington, VA104 štúdií
- Nashville, TN97 štúdií
- Boston, MA90 štúdií
- Los Angeles, CA87 štúdií
- St. Louis, MO73 štúdií
- Chicago, IL61 štúdií
- Baltimore, MD60 štúdií
- San Antonio, TX59 štúdií
- Columbus, OH57 štúdií
- Washington, DC55 štúdií
Iné štúdie v Akron
- Rakovina pľúc16 štúdií
- Rakovina prsníka13 štúdií
- Rakovina (všetky typy)13 štúdií
- Rakovina prostaty9 štúdií
- Metastatická rakovina8 štúdií
- Akútna myeloidná leukémia8 štúdií
- Malobuněčný rakovina plic8 štúdií
- Melanóm8 štúdií
- Kolorektálny karcinóm8 štúdií
- Steatotické ochorenie pečene7 štúdií
- Schizofrénia6 štúdií
- Cievna mozgová príhoda6 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.